Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
52
DAWN Quote, Financials, Valuation and Earnings
Last price:
$9.61
Seasonality move
:
-22.78%
Day range:
$9.51 - $9.82
52-week range:
$5.64 - $13.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.37x
P/B ratio:
2.19x
Volume:
931.1K
Avg. volume:
2.9M
1-year change:
-24.23%
Market cap:
$985.7M
Revenue:
$131.2M
EPS (TTM):
-$1.49
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$37.8M | -$0.28 | 50.99% | -69.07% | $22.25 |
|
CATX
Perspective Therapeutics, Inc.
|
$206.8K | -$0.32 | -9.65% | -37.91% | $12.3077 |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$72.8M | -$0.26 | 11.5% | -35.2% | $8.35 |
|
IRTC
iRhythm Technologies, Inc.
|
$184.7M | -$0.28 | 21.67% | -80.89% | $218.60 |
|
LNTH
Lantheus Holdings, Inc.
|
$364.5M | $1.27 | -5.55% | -29.39% | $82.43 |
|
MRSN
Mersana Therapeutics, Inc.
|
$13.7M | -$0.89 | -69.75% | -14.49% | $33.20 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$9.60 | $22.25 | $985.7M | -- | $0.00 | 0% | 7.37x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8150 | $12.3077 | $209.3M | -- | $0.00 | 0% | 190.87x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$2.87 | $8.35 | $1.1B | -- | $0.00 | 0% | 3.80x |
|
IRTC
iRhythm Technologies, Inc.
|
$175.80 | $218.60 | $5.7B | -- | $0.00 | 0% | 7.95x |
|
LNTH
Lantheus Holdings, Inc.
|
$66.68 | $82.43 | $4.4B | 28.01x | $0.00 | 0% | 3.04x |
|
MRSN
Mersana Therapeutics, Inc.
|
$29.10 | $33.20 | $145.1M | -- | $0.00 | 0% | 56.57x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
|
0.64% | 0.642 | 0.4% | 8.29x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
6.96% | -0.206 | 6.28% | 2.92x |
|
IRTC
iRhythm Technologies, Inc.
|
85.74% | 2.140 | 13.23% | 4.47x |
|
LNTH
Lantheus Holdings, Inc.
|
35.63% | -1.491 | 18.22% | 2.30x |
|
MRSN
Mersana Therapeutics, Inc.
|
-4.01% | -0.289 | 5.93% | 1.32x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$35.3M | -$24.3M | -30.8% | -30.98% | -60.94% | -$5.8M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$20M | -$89.8M | -50.35% | -54.43% | -133.06% | -$89.5M |
|
IRTC
iRhythm Technologies, Inc.
|
$137.1M | -$4M | -6.2% | -54.18% | -2.08% | $20.1M |
|
LNTH
Lantheus Holdings, Inc.
|
$222.4M | $43.6M | 9.52% | 14.66% | 11.36% | $94.7M |
|
MRSN
Mersana Therapeutics, Inc.
|
$10.9M | -$7.5M | -689.85% | -533.43% | -67.68% | -$3.2M |
Day One Biopharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns DAWN or CATX?
Perspective Therapeutics, Inc. has a net margin of -49.57% compared to Day One Biopharmaceuticals, Inc.'s net margin of -12425.36%. Day One Biopharmaceuticals, Inc.'s return on equity of -30.98% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.74% -$0.19 $453.8M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About DAWN or CATX?
Day One Biopharmaceuticals, Inc. has a consensus price target of $22.25, signalling upside risk potential of 131.77%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 349.19%. Given that Perspective Therapeutics, Inc. has higher upside potential than Day One Biopharmaceuticals, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Day One Biopharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.5 1 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is DAWN or CATX More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock DAWN or CATX?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or CATX?
Day One Biopharmaceuticals, Inc. quarterly revenues are $39.8M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Day One Biopharmaceuticals, Inc.'s net income of -$19.7M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 7.37x versus 190.87x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.7.37x -- $39.8M -$19.7M CATXPerspective Therapeutics, Inc.190.87x -- $209K -$26M
-
Which has Higher Returns DAWN or IOVA?
Iovance Biotherapeutics, Inc. has a net margin of -49.57% compared to Day One Biopharmaceuticals, Inc.'s net margin of -135.28%. Day One Biopharmaceuticals, Inc.'s return on equity of -30.98% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.74% -$0.19 $453.8M IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M -
What do Analysts Say About DAWN or IOVA?
Day One Biopharmaceuticals, Inc. has a consensus price target of $22.25, signalling upside risk potential of 131.77%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.35 which suggests that it could grow by 190.94%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Day One Biopharmaceuticals, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Day One Biopharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.5 1 0 IOVAIovance Biotherapeutics, Inc.6 4 1 -
Is DAWN or IOVA More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.288%.
-
Which is a Better Dividend Stock DAWN or IOVA?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or IOVA?
Day One Biopharmaceuticals, Inc. quarterly revenues are $39.8M, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. Day One Biopharmaceuticals, Inc.'s net income of -$19.7M is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 7.37x versus 3.80x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.7.37x -- $39.8M -$19.7M IOVAIovance Biotherapeutics, Inc.3.80x -- $67.5M -$91.3M
-
Which has Higher Returns DAWN or IRTC?
iRhythm Technologies, Inc. has a net margin of -49.57% compared to Day One Biopharmaceuticals, Inc.'s net margin of -2.7%. Day One Biopharmaceuticals, Inc.'s return on equity of -30.98% beat iRhythm Technologies, Inc.'s return on equity of -54.18%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.74% -$0.19 $453.8M IRTCiRhythm Technologies, Inc.71.09% -$0.16 $854.9M -
What do Analysts Say About DAWN or IRTC?
Day One Biopharmaceuticals, Inc. has a consensus price target of $22.25, signalling upside risk potential of 131.77%. On the other hand iRhythm Technologies, Inc. has an analysts' consensus of $218.60 which suggests that it could grow by 24.35%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than iRhythm Technologies, Inc., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than iRhythm Technologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.5 1 0 IRTCiRhythm Technologies, Inc.11 2 0 -
Is DAWN or IRTC More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iRhythm Technologies, Inc. has a beta of 1.099, suggesting its more volatile than the S&P 500 by 9.93%.
-
Which is a Better Dividend Stock DAWN or IRTC?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. iRhythm Technologies, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or IRTC?
Day One Biopharmaceuticals, Inc. quarterly revenues are $39.8M, which are smaller than iRhythm Technologies, Inc. quarterly revenues of $192.9M. Day One Biopharmaceuticals, Inc.'s net income of -$19.7M is lower than iRhythm Technologies, Inc.'s net income of -$5.2M. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while iRhythm Technologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 7.37x versus 7.95x for iRhythm Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.7.37x -- $39.8M -$19.7M IRTCiRhythm Technologies, Inc.7.95x -- $192.9M -$5.2M
-
Which has Higher Returns DAWN or LNTH?
Lantheus Holdings, Inc. has a net margin of -49.57% compared to Day One Biopharmaceuticals, Inc.'s net margin of 7.23%. Day One Biopharmaceuticals, Inc.'s return on equity of -30.98% beat Lantheus Holdings, Inc.'s return on equity of 14.66%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.74% -$0.19 $453.8M LNTHLantheus Holdings, Inc.57.91% $0.41 $1.7B -
What do Analysts Say About DAWN or LNTH?
Day One Biopharmaceuticals, Inc. has a consensus price target of $22.25, signalling upside risk potential of 131.77%. On the other hand Lantheus Holdings, Inc. has an analysts' consensus of $82.43 which suggests that it could grow by 23.62%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than Lantheus Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.5 1 0 LNTHLantheus Holdings, Inc.9 2 0 -
Is DAWN or LNTH More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Lantheus Holdings, Inc. has a beta of -0.102, suggesting its less volatile than the S&P 500 by 110.17%.
-
Which is a Better Dividend Stock DAWN or LNTH?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lantheus Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. Lantheus Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or LNTH?
Day One Biopharmaceuticals, Inc. quarterly revenues are $39.8M, which are smaller than Lantheus Holdings, Inc. quarterly revenues of $384M. Day One Biopharmaceuticals, Inc.'s net income of -$19.7M is lower than Lantheus Holdings, Inc.'s net income of $27.8M. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while Lantheus Holdings, Inc.'s PE ratio is 28.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 7.37x versus 3.04x for Lantheus Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.7.37x -- $39.8M -$19.7M LNTHLantheus Holdings, Inc.3.04x 28.01x $384M $27.8M
-
Which has Higher Returns DAWN or MRSN?
Mersana Therapeutics, Inc. has a net margin of -49.57% compared to Day One Biopharmaceuticals, Inc.'s net margin of -68.54%. Day One Biopharmaceuticals, Inc.'s return on equity of -30.98% beat Mersana Therapeutics, Inc.'s return on equity of -533.43%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.74% -$0.19 $453.8M MRSNMersana Therapeutics, Inc.99.25% -$1.51 -$57.2M -
What do Analysts Say About DAWN or MRSN?
Day One Biopharmaceuticals, Inc. has a consensus price target of $22.25, signalling upside risk potential of 131.77%. On the other hand Mersana Therapeutics, Inc. has an analysts' consensus of $33.20 which suggests that it could grow by 14.09%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than Mersana Therapeutics, Inc., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than Mersana Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.5 1 0 MRSNMersana Therapeutics, Inc.0 7 0 -
Is DAWN or MRSN More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mersana Therapeutics, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.856%.
-
Which is a Better Dividend Stock DAWN or MRSN?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mersana Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. Mersana Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or MRSN?
Day One Biopharmaceuticals, Inc. quarterly revenues are $39.8M, which are larger than Mersana Therapeutics, Inc. quarterly revenues of $11M. Day One Biopharmaceuticals, Inc.'s net income of -$19.7M is lower than Mersana Therapeutics, Inc.'s net income of -$7.5M. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while Mersana Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 7.37x versus 56.57x for Mersana Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.7.37x -- $39.8M -$19.7M MRSNMersana Therapeutics, Inc.56.57x -- $11M -$7.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
